DJO reported 3Q19 orthopedic revenue of USD $97.9MM, +5.9% vs. 3Q18.
- Colfax leadership says it is off to a strong start implementing operational efficiencies at DJO through their CBS program
- Surgeon conversions and new products like the AltiVate shoulder, EMPOWR Knee and AltiVate Reverse Short Stem drove joint replacement revenue growth
- Leadership believes it can sustain consistent high single-digit growth for joint replacement
- The company is actively working a “healthy funnel” of bolt-on acquisitions to accelerate growth in 2020
- ORTHOWORLD projects DJO full year 2019 orthopedic revenue of $411.2MM, +5.5% vs. 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
| |
3Q19 |
3Q18 |
$ Chg |
% Chg |
| Joint Replacement |
$75.9 |
$70.9 |
$5.0 |
7.1% |
| Knees |
$19.5 |
$18.5 |
$1.0 |
5.6% |
| Hips |
$16.7 |
$16.1 |
$0.7 |
4.3% |
| Extremities |
$39.6 |
$36.4 |
$3.3 |
9.0% |
| Other (Recovery Sciences) |
$22.0 |
$21.5 |
$0.5 |
2.3% |
| Total |
$97.9 |
$92.4 |
$5.5 |
5.9% |
| |
9Mo 19 |
9Mo 18 |
$ Chg |
% Chg |
| Joint Replacement |
$230.5 |
$217.7 |
$12.7 |
5.9% |
| Knees |
$59.9 |
$56.8 |
$3.1 |
5.5% |
| Hips |
$51.0 |
$49.3 |
$1.7 |
3.5% |
| Extremities |
$119.5 |
$111.6 |
$7.9 |
7.1% |
| Other (Recovery Sciences) |
$64.4 |
$65.5 |
-$1.1 |
-1.6% |
| Total |
$294.9 |
$283.2 |
$11.7 |
4.1% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
